Industry news
Novartis sells influenza vaccines to CSL Ltd for $275 million effective 2015
Novartis announced it has entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of $ 275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.The influenza vaccine business includes the Fluad trivalent seasonal vaccine and the Flucelvax pandemic vaccines.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins